nach oben

Erschienen in:

01.10.2014 | Original article

Stereotactic body radiotherapy for liver tumors

Principles and practical guidelines of the DEGRO Working Group on Stereotactic Radiotherapy

verfasst von: PD Dr. Florian Sterzing, Thomas B. Brunner, Iris Ernst, Wolfgang W. Baus, Burkhard Greve, Klaus Herfarth, Matthias Guckenberger

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 10/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This report of the Working Group on Stereotactic Radiotherapy of the German Society of Radiation Oncology (DEGRO) aims to provide a practical guideline for safe and effective stereotactic body radiotherapy (SBRT) of liver tumors.

Methods

The literature on the clinical evidence of SBRT for both primary liver tumors and liver metastases was reviewed and analyzed focusing on both physical requirements and special biological characteristics.

Results

Recommendations were developed for patient selection, imaging, planning, treatment delivery, motion management, dose reporting, and follow-up. Radiation dose constraints to critical organs at risk are provided.

Conclusion

SBRT is a well-established treatment option for primary and secondary liver tumors associated with low morbidity.

Adam R, Chiche L, Aloia T et al (2006) Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1,452 patients and development of a prognostic model. Ann Surg 244:524–535PubMedCrossRefPubMedCentral

Almaghrabi MY, Supiot S, Paris F et al (2012) Stereotactic body radiation therapy for abdominal oligometastases: a biological and clinical review. Radiat Oncol 7:126PubMedCrossRefPubMedCentral

Ambrosino G, Polistina F, Costantin G et al (2009) Image-guided robotic stereotactic radiosurgery for unresectable liver metastases: preliminary results. Anticancer Res 29:3381–3384PubMed

Andolino DL, Johnson CS, Maluccio M et al (2011) Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 81:e447–e453PubMedCrossRef

Bae SH, Kim MS, Cho CK et al (2012) Predictor of severe gastroduodenal toxicity after stereotactic body radiotherapy for abdominopelvic malignancies. Int J Radiat Oncol Biol Phys 84:e469–e474PubMedCrossRef

Barney BM, Olivier KR, Miller RC et al (2012) Clinical outcomes and toxicity using stereotactic body radiotherapy (SBRT) for advanced cholangiocarcinoma. Radiat Oncol 7:67PubMedCrossRefPubMedCentral

Benedict SH, Yenice KM, Followill D et al (2010) Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys 37:4078–4101PubMedCrossRef

Bloemen-Van Gurp E, Van Der Meer S, Hendry J et al (2013) Active breathing control in combination with ultrasound imaging: a feasibility study of image guidance in stereotactic body radiation therapy of liver lesions. Int J Radiat Oncol Biol Phys 85:1096–1102PubMedCrossRef

Boda-Heggemann J, Dinter D, Weiss C et al (2012) Hypofractionated image-guided breath-hold SABR (stereotactic ablative body radiotherapy) of liver metastases-clinical results. Radiat Oncol 7:92PubMedCrossRefPubMedCentral

10.

Brown JM, Koong AC (2008) High-dose single-fraction radiotherapy: exploiting a new biology? Int J Radiat Oncol Biol Phys 71:324–325PubMedCrossRef

11.

Brunner TB, Eccles CL (2010) Radiotherapy and chemotherapy as therapeutic strategies in extrahepatic biliary duct carcinoma. Strahlenther Onkol 186:672–680PubMedCrossRef

12.

Bujold A, Massey CA, Kim JJ et al (2013) Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol 31:1631–1639PubMedCrossRef

13.

Buther F, Ernst I, Dawood M et al (2010) Detection of respiratory tumour motion using intrinsic list mode-driven gating in positron emission tomography. Eur J Nucl Med Mol Imaging 37:2315–2327PubMedCrossRef

14.

Case RB, Moseley DJ, Sonke JJ et al (2010) Interfraction and intrafraction changes in amplitude of breathing motion in stereotactic liver radiotherapy. Int J Radiat Oncol Biol Phys 77:918–925PubMedCrossRef

15.

Case RB, Sonke JJ, Moseley DJ et al (2009) Inter- and intrafraction variability in liver position in non-breath-hold stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 75:302–308PubMedCrossRef

16.

Chang DT, Swaminath A, Kozak M et al (2011) Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer 117:4060–4069PubMedCrossRef

17.

Dhanasekaran R, Hemming AW, Zendejas I et al (2013) Treatment outcomes and prognostic factors of intrahepatic cholangiocarcinoma. Oncol Rep 29:1259–1267PubMedPubMedCentral

18.

Dieterich S, Cavedon C, Chuang CF et al (2011) Report of AAPM TG 135: quality assurance for robotic radiosurgery. Med Phys 38:2914–2936PubMedCrossRef

19.

Fong Y, Salo J (1999) Surgical therapy of hepatic colorectal metastasis. Semin Oncol 26:514–523PubMed

20.

Garcea G, Lloyd TD, Aylott C et al (2003) The emergent role of focal liver ablation techniques in the treatment of primary and secondary liver tumours. Eur J Cancer 39:2150–2164PubMedCrossRef

21.

Ge J, Santanam L, Noel C et al (2013) Planning 4-dimensional computed tomography (4DCT) cannot adequately represent daily intrafractional motion of abdominal tumors. Int J Radiat Oncol Biol Phys 85:999–1005PubMedCrossRef

22.

Goodman KA, Wiegner EA, Maturen KE et al (2010) Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys 78:486–493PubMedCrossRef

23.

Guckenberger M, Andratschke N, Alheit H et al (2014) Definition of stereotactic body radiotherapy: principles and practice for the treatment of stage I non-small cell lung cancer. Strahlenther Onkol 190:26–33PubMedCrossRefPubMedCentral

24.

Guckenberger M, Richter A, Boda-Heggemann J et al (2012) Motion compensation in radiotherapy. Crit Rev Biomed Eng 40:187–197PubMedCrossRef

25.

Habermehl D, Herfarth KK, Bermejo JL et al (2013) Single-dose radiosurgical treatment for hepatic metastases—therapeutic outcome of 138 treated lesions from a single institution. Radiat Oncol 8:175PubMedCrossRefPubMedCentral

26.

Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13:8–10PubMed

27.

Herfarth KK, Debus J, Lohr F et al (2001) Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. J Clin Oncol 19:164–170PubMed

28.

Herfarth KK, Debus J, Lohr F et al (2001) Stereotactic irradiation of liver metastases. Radiologe 41:64–68PubMedCrossRef

29.

Herfarth KK, Hof H, Bahner ML et al (2003) Assessment of focal liver reaction by multiphasic CT after stereotactic single-dose radiotherapy of liver tumors. Int J Radiat Oncol Biol Phys 57:444–451PubMedCrossRef

30.

House MG, Ito H, Gonen M et al (2010) Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg 210:744–752, 752–745PubMedCrossRef

31.

Hoyer M, Roed H, Traberg Hansen A et al (2006) Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol 45:823–830PubMedCrossRef

32.

Huang WY, Jen YM, Lee MS et al (2012) Stereotactic body radiation therapy in recurrent hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 84:355–361PubMedCrossRef

33.

Ibarra RA, Rojas D, Snyder L et al (2012) Multicenter results of stereotactic body radiotherapy (SBRT) for non-resectable primary liver tumors. Acta Oncol 51:575–583PubMedCrossRef

34.

Iwata H, Shibamoto Y, Hashizume C et al (2010) Hypofractionated stereotactic body radiotherapy for primary and metastatic liver tumors using the novalis image-guided system: preliminary results regarding efficacy and toxicity. Technol Cancer Res Treat 9:619–627PubMed

35.

Jung J, Yoon SM, Kim SY et al (2013) Radiation-induced liver disease after stereotactic body radiotherapy for small hepatocellular carcinoma: clinical and dose-volumetric parameters. Radiat Oncol 8:249PubMedCrossRefPubMedCentral

36.

Kavanagh BD, Mcgarry RC, Timmerman RD (2006) Extracranial radiosurgery (stereotactic body radiation therapy) for oligometastases. Semin Radiat Oncol 16:77–84PubMedCrossRef

37.

Kavanagh BD, Schefter TE, Cardenes HR et al (2006) Interim analysis of a prospective phase I/II trial of SBRT for liver metastases. Acta Oncol 45:848–855PubMedCrossRef

38.

Kawahara D, Ozawa S, Nakashima T et al (2014) Availability of using diaphragm matching in stereotactic body radiotherapy (SBRT) at the time in breath-holding SBRT for liver cancer. Nihon Hoshasen Gijutsu Gakkai Zasshi 70:51–56PubMedCrossRef

39.

Keall PJ, Mageras GS, Balter JM et al (2006) The management of respiratory motion in radiation oncology report of AAPM Task Group 76. Med Phys 33:3874–3900PubMedCrossRef

40.

Klein J, Dawson LA (2013) Hepatocellular carcinoma radiation therapy: review of evidence and future opportunities. Int J Radiat Oncol Biol Phys 87:22–32PubMedCrossRef

41.

Kopek N, Holt MI, Hansen AT et al (2010) Stereotactic body radiotherapy for unresectable cholangiocarcinoma. Radiother Oncol 94:47–52PubMedCrossRef

42.

Kruis MF, Van De Kamer JB, Sonke JJ et al (2013) Registration accuracy and image quality of time averaged mid-position CT scans for liver SBRT. Radiother Oncol 109:404–408PubMedCrossRef

43.

Kwon JH, Bae SH, Kim JY et al (2010) Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer. BMC Cancer 10:475PubMedCrossRefPubMedCentral

44.

Lee MT, Kim JJ, Dinniwell R et al (2009) Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol 27:1585–1591PubMedCrossRef

45.

Louis C, Dewas S, Mirabel X et al (2010) Stereotactic radiotherapy of hepatocellular carcinoma: preliminary results. Technol Cancer Res Treat 9:479–487PubMed

46.

Mancosu P, Castiglioni S, Reggiori G et al (2012) Stereotactic body radiation therapy for liver tumours using flattening filter free beam: dosimetric and technical considerations. Radiat Oncol 7:16PubMedCrossRefPubMedCentral

47.

Mccammon R, Schefter TE, Gaspar LE et al (2009) Observation of a dose-control relationship for lung and liver tumors after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 73:112–118PubMedCrossRef

48.

Mendez Romero A, Hoyer M (2012) Radiation therapy for liver metastases. Curr Opin Support Palliat Care 6:97–102PubMedCrossRef

49.

Mendez Romero A, Wunderink W, Hussain SM et al (2006) Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase I-II study. Acta Oncol 45:831–837PubMedCrossRef

50.

Milano MT, Katz AW, Zhang H et al (2012) Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys 83:878–886PubMedCrossRef

51.

Mohnike K, Wieners G, Schwartz F et al (2010) Computed tomography-guided high-dose-rate brachytherapy in hepatocellular carcinoma: safety, efficacy, and effect on survival. Int J Radiat Oncol Biol Phys 78:172–179PubMedCrossRef

52.

Momm F, Schubert E, Henne K et al (2010) Stereotactic fractionated radiotherapy for Klatskin tumours. Radiother Oncol 95:99–102PubMedCrossRef

53.

Nahum AE, Uzan J (2012) (Radio)biological optimization of external-beam radiotherapy. Comput Math Methods Med 2012:329214PubMedCrossRefPubMedCentral

54.

Nordlinger B, Guiguet M, Vaillant JC et al (1996) Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 77:1254–1262PubMedCrossRef

55.

Park JC, Park SH, Kim JH et al (2012) Liver motion during cone beam computed tomography guided stereotactic body radiation therapy. Med Phys 39:6431–6442PubMedCrossRef

56.

Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108PubMedCrossRef

57.

Polistina FA, Guglielmi R, Baiocchi C et al (2011) Chemoradiation treatment with gemcitabine plus stereotactic body radiotherapy for unresectable, non-metastatic, locally advanced hilar cholangiocarcinoma. Results of a five year experience. Radiother Oncol 99:120–123PubMedCrossRef

58.

Reddy SK, Barbas AS, Marroquin CE et al (2007) Resection of noncolorectal nonneuroendocrine liver metastases: a comparative analysis. J Am Coll Surg 204:372–382PubMedCrossRef

59.

Ricke J, Mohnike K, Pech M et al (2010) Local response and impact on survival after local ablation of liver metastases from colorectal carcinoma by computed tomography-guided high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 78:479–485PubMedCrossRef

60.

Robertson DJ, Stukel TA, Gottlieb DJ et al (2009) Survival after hepatic resection of colorectal cancer metastases: a national experience. Cancer 115:752–759PubMedCrossRefPubMedCentral

61.

Ruers T, Punt C, Van Coevorden F et al (2012) Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol 23:2619–2626PubMedCrossRefPubMedCentral

62.

Rule W, Timmerman R, Tong L et al (2011) Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases. Ann Sur Oncol 18:1081–1087CrossRef

63.

Rusthoven KE, Kavanagh BD, Cardenes H et al (2009) Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 27:1572–1578PubMedCrossRef

64.

Schefter TE, Kavanagh BD, Timmerman RD et al (2005) A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys 62:1371–1378PubMedCrossRef

65.

Scorsetti M, Arcangeli S, Tozzi A et al (2013) Is stereotactic body radiation therapy an attractive option for unresectable liver metastases? A preliminary report from a phase 2 trial. Int J Radiat Oncol Biol Phys 86:336–342PubMedCrossRef

66.

Seo YS, Kim MS, Yoo SY et al (2010) Preliminary result of stereotactic body radiotherapy as a local salvage treatment for inoperable hepatocellular carcinoma. J Surg Oncol 102:209–214PubMedCrossRef

67.

Sherman M, Burak K, Maroun J et al (2011) Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma. Curr Oncol 18:228–240PubMedCrossRefPubMedCentral

68.

Small R, Lubezky N, Ben-Haim M (2007) Current controversies in the surgical management of colorectal cancer metastases to the liver. Isr Med Assoc J 9:742–747PubMed

69.

Smith MD, Mccall JL (2009) Systematic review of tumour number and outcome after radical treatment of colorectal liver metastases. Br J Sur 96:1101–1113CrossRef

70.

Sterzing F, Munter MW, Schafer M et al (2005) Radiobiological investigation of dose-rate effects in intensity-modulated radiation therapy. Strahlenther Onkol 181:42–48PubMedCrossRef

71.

Sudan D, Deroover A, Chinnakotla S et al (2002) Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. Am J Transplant 2:774–779PubMedCrossRef

72.

Takeda A, Takahashi M, Kunieda E et al (2008) Hypofractionated stereotactic radiotherapy with and without transarterial chemoembolization for small hepatocellular carcinoma not eligible for other ablation therapies: preliminary results for efficacy and toxicity. Hepatol Res 38:60–69PubMedCrossRef

73.

Tse RV, Hawkins M, Lockwood G et al (2008) Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 26:657–664PubMedCrossRef

74.

Wei AC, Greig PD, Grant D et al (2006) Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann Surg Oncol 13:668–676PubMedCrossRef

75.

Wieners G, Mohnike K, Peters N et al (2011) Treatment of hepatic metastases of breast cancer with CT-guided interstitial brachytherapy—a phase II-study. Radiother Oncol 100:314–319PubMedCrossRef

76.

Wong SL, Mangu PB, Choti MA et al (2010) American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol 28:493–508PubMedCrossRef

77.

Yang W, Fraass BA, Reznik R et al (2014) Adequacy of inhale/exhale breathhold CT based ITV margins and image-guided registration for free-breathing pancreas and liver SBRT. Radiat Oncol 9:11PubMedCrossRefPubMedCentral

Titel: Stereotactic body radiotherapy for liver tumors
Principles and practical guidelines of the DEGRO Working Group on Stereotactic Radiotherapy
verfasst von: PD Dr. Florian Sterzing
Thomas B. Brunner
Iris Ernst
Wolfgang W. Baus
Burkhard Greve
Klaus Herfarth
Matthias Guckenberger
Publikationsdatum: 01.10.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 10/2014
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-014-0714-1

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Stereotactic body radiotherapy for liver tumors

Principles and practical guidelines of the DEGRO Working Group on Stereotactic Radiotherapy

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2014

Response to the letter to the editor by Genc et al.

Mitteilungen der Fachgesellschaften

FET-PET-based reirradiation and chloroquine in patients with recurrent glioblastoma

How nescience may obscure evidence

Inverse prognostic impact of ErbB2 mRNA and protein expression level in tumors of soft tissue sarcoma patients

Professor Dr. Fridtjof Nüsslin zum 75. Geburtstag

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie